M Rauch
Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial
Korfel A, Birnbaum T, Kirchen H, Mergenthaler H, Schubert J, Berdel W, Birkmann J, Hummel M, Thiel E, Leithäuser M, Hundsberger T, Weller M, Martus P, Roth P, Klasen H, Roeth A, Rauch M, Hertenstein B, Fischer T, Fischer L. Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. Ann Oncol 2012; 23:2374-2380.
05.03.2012Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial
05.03.2012Ann Oncol 2012; 23:2374-2380
Korfel A, Birnbaum T, Kirchen H, Mergenthaler H-G, Schubert J, Berdel W, Birkmann J, Hummel M, Thiel E, Leithäuser M, Hundsberger Thomas, Weller M, Martus P, Roth P, Klasen H A, Roeth A, Rauch M, Hertenstein B, Fischer T, Fischer L
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma
Hau P, Koch H, Jauch T, Schuth J, Rieckmann P, Brenner A, Rauch M, Rudolph R, Bauer B, Marg E, Hundsberger T, Koch D, Bogdahn U. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 2007; 68:688-90.
27.02.2007Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma
27.02.2007Neurology 2007; 68:688-90
Hau P, Koch H, Jauch T, Schuth J, Rieckmann P, Brenner A, Rauch M, Rudolph R, Bauer B, Marg E, Hundsberger Thomas, Koch D, Bogdahn U